WO1998027967A1 - Release-controlled coated tablets - Google Patents

Release-controlled coated tablets

Info

Publication number
WO1998027967A1
WO1998027967A1 PCT/DK1997/000582 DK9700582W WO1998027967A1 WO 1998027967 A1 WO1998027967 A1 WO 1998027967A1 DK 9700582 W DK9700582 W DK 9700582W WO 1998027967 A1 WO1998027967 A1 WO 1998027967A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
core
tablet according
tablet
eudragit
coating
Prior art date
Application number
PCT/DK1997/000582
Other languages
French (fr)
Inventor
LARSEN Annette RÖMMELMAYER
Steen Pedersen
Original Assignee
Dumex-Alpharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Abstract

A tablet suitable for oral administration being formed from the following ingredients: a) an inner core containing a biologically active agent and conventional excipients (part B) and a pharmaceutically acceptable, water insoluble, non-swellable carrier (part A), wherein part A constitutes from 20 % to 70 % by weight of the core; b) an entering coating, which prevents gastric fluid to enter into the core thereby preventing drug release in the stomach, but being soluble in the intestinal fluid (pH > 5); and c) an outer coating consisting of one or more polymer(s), the permeability of which is independent of pH.

Description

Release-controlled coated tablets.

The present invention is concerned with a novel delivery system for targeting a wide variety of therapeutically active medicaments to the intestine and/or the colon. The delivery system is a tablet suitable for oral administration and comprising three parts:

a) an inner core containing a biologically active ingredient and conventional excipients,

b) an enteric coating, which prevents gastric fluid to enter into the core thereby preventing drug release in the stomach, but being soluble in the intestinal fluid (pH > 5 ) , and

c) an outer coating consisting of one or more polymer (s) . The permeability of the outer coating is independent of the pH value, therefore the release of the drug is largely unaffected by individual variations in the gastrointestinal fluids.

Among the biologically active agents which can advantageously be formulated and orally administrated in form of the tablet of the present invention, there are considered in particular active agents for which a delayed effect and/or a local effect are desired.

In a first aspect of the present invention the tablet can be used to provide controlled/delayed effect over a desired period of time.

In a further aspect of the present invention the tablet is especially suitable for time-varying delivery of a drug, the s.c. chronobiologically mode of action. E.g. patients with elevated blood pressure experience that their blood pressure has within-day rhytmicity and that high pressure values are often seen in the morning just after the patient has woken up. Treatment of the rise in blood pressure just after awakening requires a dosage form that is administrated at bed-time and delivers the drug after a predetermined drug free period. Examples of drugs which beneficially can be delivered in this way are calcium antagonists like e.g. verapamil.

Other Examples of drugs, which are advantageously delivered in a release-controlled manner, are organic nitrates like e.g. glyceryl trinitrate or isosorbide nitrates. Especially preferred is isosorbide-5- mononitrate, (1,4:3, 6-dianhydro-D-glucitol-5- mononitrate) .

Isosorbide-5-mononitrate (5-ISMN) is a vasodilator and an arterial dilator. 5-ISMN is an active metabolite of 2,5- isosorbide-dinitrate, which have been used in treatment of angina pectoris for many years. Unlike the parent compound, 5-ISMN does not undergo hepatic first-pass metabolism, thus providing for a greater systemic bioavailability of the mononitrate dose. 5-ISMN is also completely absorbed from the gastrointestinal tract after oral administration and has a much longer half-life than isosorbide dinitrate. These factors make 5-ISMN a more attractive form of nitrate therapy for the management of angina and also for the development of long-acting oral nitrate forms.

It is obvious, that once-a-day dosing of a drug has advantages over twice- or three times a day dosing regimens, both from a patient compliance point of view but also because it prevents unwanted side-effects like high peak/low through plasma profile. However, if a controlled release form of 5-ISMN gives a serum con- centration more than 100 ng/ml constantly during 24 hours, development of tolerance is likely to occur.

Nitrate tolerance may be defined as that condition where the haemodynamic responsiveness of the target tissue is lost. Whilst the direct cause of nitrate tolerance is unknown, a possibility may be changes in pharmacokinetics or to alterations in the property of target tissues such as the arterial and venal smooth muscle, making them less sensitive to the nitrate effect.

Nitrate therapy is the oldest treatment regimen for angina pectoris and the phenomenon of nitrate tolerance has been observed in humans with all commonly known nitrates, regardless of route of administration. 5-ISMN is no exception, and a need exists to design a form that overcomes this tolerance effect.

Another well-known problem to those skilled in the art of treating angina is that many angina patients chronically experience discomfort during sleep, just before awakening and for the first hour or so upon awakening. A further need exists to a form which overcomes this problem.

In US 4.956.181 to Eastman Kodak, a nitrate drug for angina pectoris is disclosed, more specifically a method and a transdermal patch for treating angina pectoris and preventing tolerance to nitrate drugs which takes into account the frequent need to provide the patient with relief or prevention of pre-waking or early morning angina. The treatment comprises administrating a daily unit dose of the nitrate before bedtime in a transdermal dosage form that provides a washout period of 3-12 hours by sufficiently retarding delivery of the nitrate from the patch to the patient during the washout period so as to provide a rate of delivery of nitrate that is so low as to be insufficient to cause tolerance to said nitrate in said patient.

Dutch patent No. NL 155 452 to SANOL-ARZNEIMITTEL DR SCHWARZ describes release controlled tablets consisting of a granulate containing 5-ISMN, talc and sugar with controlled, linear release.

EP 163 000 B to ZERBE, H., KETTELHACK RIKER PH; 3 M MEDICA GMBH deals with controlled release pharmaceutical pellet, in which entero soluble core is coated with impermeable layer, 5-ISMN-containing depot layer and release-controlling layer.

JP 93087488 B to TOA EIYO KK concerns a sustained release preparation of hardly soluble medicine, e.g. 5-ISMN, - by pelletising mixture of 5-ISMN with release control substance and swelling high molecular weight polymer.

EP 219 161 to EURAND ITALIA describes a process for the preparation of stabilised 5-ISMN tablets, being also of sustained release, and form thus obtained. The tablets are containing PVP & hydroxypropyl methylcellulose .

In JP 62126127 to KANEBO, production of long-releasing 5- ISMN preparation by spray coating with a solution of ethylcellulose and macrogol is disclosed.

EP 240 351 to HANS LOWEY discloses a method of preparing controlled long acting pharmaceutical forms in unit dosage form having uniform and comparable bioavailability characteristics in which cellulose derivatives is mixed with 5-ISMN. In EP 263 083 B to ROBERTO VALDUCCI, pellets with a medicament layer (e.g. 5-ISMN ) applied thereon is coated with a membrane of steric acid & ethylcellulose . Sustained release from 4-22 h. is achieved.

EP 325 843 to ELAN CORP. discloses 5-ISMN oral and transdermal compositions, e.g. a once-a-day tablet. Onto non-parail seeds 5-ISMN, acid/diluent are applied and polymer blend is superimposed onto the core, which is then coated with a mix. of water-insoluble & ( and to a lesser degree) water-soluble polymer, e.g. Eudragit RS© and RL®. The tablet insures a therapeutic level of ISMN in 14-18 h. followed by a wash-out period to prevent tolerance .

EP 396 425 B to KV PHARM. CO. deals with extended release oral pharmaceutical compositions containing 5-ISMN, comprising a mixture of immediate release and coated particles for release of drug over 12-24 h. Membrane coating of the particles may be with Eudragit®.

In EP 477061, PIERRE FABRE MEDICAMENT discloses prolonged release 5-ISMN tablets - used for angina and cardiac insufficiency treatment.

The granulate comprises 5-ISMN, swelling agent, e.g. hydrophilic polymer & diluent.

WO 92/05774 to SCHWARZ PHARMA describes an orally administrated solvent free pharmaceutical preparation with delayed 5-ISMN release, in which 5-ISMN is dissolved in a matrix of polyvinylacrylate .

FREUND INDUSTRIAL CO. LDT . discloses in EP 482 576 a prolonged release dosage form of 5-ISMN and method, in which 5-ISMN is microincapsulated with a water insoluble material, e.g. hydrophobic polymers. The microcapsules are then granulated and tabletted by conventional methods .

WO 9406414 to YAMANOUCHI concerns sustained-release preparation which releases 5-ISMN in the lower intestine for stable, sustained release, in the form of a matrix tablet consisting of 5-ISMN dissolved in hydrogel forming polymer, capable of swelling and releasing the active drug in the gastrointestinal tract.

WO 94/25010 to BYK NEDERLAND discloses a solid form of administration of 5-ISMN. An inert core with a first layer of 5-ISMN, PEG, PVP & HPMC is coated with a mixture of ethylcellulose/Eudragit 3:1 - 3:2. The release is pH independent .

WO 96/26722 to Astra discloses the use of 5-ISMN to prevent stroke in patients with isolated systolic hypertension.

In the following 2 patents, 5-ISMN is not mentioned, but technologies of relevance is described.

ROUSSEL-UCLAF describes in US 4.432.966 compressed tablets coated with two layers, the outer layer is an enterocoating persistent to acid in the stomach, the inner layer having C.R. properties.

EURAND discloses in WO 91/16042 a targeted drug release form for the small intestine or colon consisting of a plurality of multidose units (< 5 mm) , having a core of drug surrounded by two membranes, i.e. an inner membrane soluble at pH >5 (e.g. Eudragit® L30D) and an outer membrane, permeable to G.I. fluids (e.g. Eudragit RS/RL). This form may be characterised by the release of no more than 10% drug at pH lower than 5 (stomach) and 90% release at pH 6-8 in 1-m h. (small intestine) .

Summary of the invention.

The general object of the invention is to provide a controlled release tablet, wherein the release of the biologically active agent is controlled in such a manner that the release is low, e.g. less than 10 %, in a first period of e.g. 1-6 hours and that the release is high, e.g. more than 80 %, and continuous in a second period of e.g. 3-12 hours.

This object is obtained with the tablet of the invention, the tablet being formed from the following ingredients:

a) an inner core containing a biologically active agent and conventional excipients (part B) and a pharmaceutically acceptable, water insoluble, non- swellable carrier (part A) , wherein part A constitutes from 20 % to 70 % by weight of the core,

b) an enteric coating, which prevents gastric fluid to enter into the core thereby preventing drug release in the stomach, but being soluble in the intestinale fluid (pH > 5) , and

c) an outer coating consisting of one or more polymer (s), the permeability of which is independent of pH.

The above-discussed release profile obtained with the tablet of the invention is believed to result from two novel factors, viz. 1) the presence of the carrier (part A) in the core and 2) the sequence of the two coatings, according to which the enteric coating constitutes the inner coating. In one of the preferred objects of the present invention the aim is to provide angina pectoris patients with a controlled release tablet, which should be administrated at bedtime, and which tablet has a nitrate-free lag time of 1-6 hours, followed by release of 5-ISMN in a controlled manner. More particularly, the preferred object of the present invention can be described in the following way:

1) At bedtime, a tablet is administrated to a patient in need thereof, which tablet contains a premeasured amount of 5-ISMN that is effective to treat angina pectoris, which tablet has controlled release properties. During the best part of the night, no 5-ISMN is released from the tablet.

2) At a pre-determined time before awakening, release of 5-ISMN starts to prevent pre-wakening or early morning angina episodes. The release of 5-ISMN continues steadily for 3-12 hours.

3) A 5-ISMN free period follows to prevent development of tolerance .

4) At bedtime, the cycle restarts.

Detailed description of the invention.

Accordingly, the invention provides a controlled release drug containing tablet for oral administration, said tablet comprising:

a) an inner core containing a biologically active agent and a pharmaceutically acceptable carrier, which carrier is modified in such a way that the dissolution is controlled,

b) an enteric coating, which prevents gastric fluid to enter into the core thereby preventing drug release in the stomach, but being soluble in the intestinal fluid (pH > 5 ) ,

c) an outer coating consisting of a mixture of one or more polymer (s) . The permeability of the outer coating is independent of the pH value, therefore the release of the drug is largely unaffected by individual variations in the gastrointestinal fluids.

The core.

To our surprise we have found that the composition of the core is a critical factor. It has become apparent that if the core dissolutes too fast it will be impossible to produce a coated tablet with a reproducible dissolution profile. On the other hand if a core with delayed dissolution is produced, it has unexpectedly been possible to create a coated tablet with a retarded dissolution profile. This can be obtained if the carrier materials consist of two parts, A and B:

Preferably part A consists of inorganic compounds consisting of alkaline-, alkaline earth- or aluminium salts which are non-toxic and pharmaceutically acceptable, e.g. water insoluble non-swellable ingredients which can be calcium phosphate, calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, calcium carbonate, calcium sulphate, calcium silicate, calcium magnesium silicate, kaolin, magnesium oxide, magnesium carbonate, aluminium silicate, silicium dioxide or titanium dioxide. Most preferred is anhydrous calcium hydrogen phosphate (also referred to as e.g. anhydrous dicalcium phosphate , which can be purchased from Mendell under the trade name Anhydrous Emcompress®. Anhydrous Emcompress® is a white, odourless and tasteless granular solid. It complies with the specifications of the United States Pharmacopeia (U.S. P.) and the Food Chemicals Codex (F.C.C.). Preferably, part A constitutes from 20% to 70%, preferably 40 % to 55 % by weight of the core.

Part B consists of a biologically active compound and conventional tabulating excipients, like e.g. diluents, binders and lubricants. Any conventional tablet formulating materials may be used to produce the core. The core may be prepared by any conventional means in the tablet-forming art, e.g. by direct compression or wet granulation method using a suitable tablet compression machine. Preferably, the granules are compressed into a tablet having a weight of 30-800 mg, preferably 200-800 mg and a hardness of 40-120 N.

In a preferred form, part A is anhydrous calcium hydrogen phosphate, part B is: diluent = a mixture of lactose and microcrystalline cellulose ( e.g. AvicelR) ) , the binder = a mixture of polyethyleneglycol 6000 and polyvinylpyrrolidone (e.g. Kollidon 30), the lubricant = a mixture of talc and magnesium stearate.

The preferred dissolution profile of the core is 30-60% dissolved drug after 1 hour, 60-90% after 2 hours and > 90% after 5 hours, (according to U.S. P. 2_3, p. 1795-96.)

The inner coating.

The inner coating is an enteric coating which prevents penetration of gastric fluid into the core, thereby preventing any drug release in the stomach. Any conventional enteric coating materials may be used in the delivery system of the invention.

Examples of enteric coating materials are hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate or acrylic- and/or methacrylic acid/ester copolymers . Preferred is such a copolymer which dissolves in media at and above pH 5. Most preferred is Eudragit®L30D, which is anionic in character and soluble in the intestine. The ratio of free carboxyl groups to ester groups is 1:1 and it is supplied as an aqueous dispersion containing 30% w/w dry polymer substance. Optionally, plastisizers can be added to the polymer film to enhance its characteristics .

The outer coating.

The outer coating consists of a pH independent erodible film, which is penetrated and partly solubilized in the gastrointestinal tract. This coating preferably consists of one or more polymer (s), e.g., ethylcellulose, polysiloxan or polyethylen or copolymers of acrylic- and/or methacrylic acids/esters like e.g those compounds sold under the trade name Eudragit®. Most preferred is Eudragit®RL or a mixture of Eudragit®RL and Eudragit® RS . Eudragit®RS is slightly permeable to gastric fluid, RL freely permeable. The difference between the two types is the ratio of quaternary ammonium groups to neutral acid esters, which is 1:40 for RS, 1:20 for RL . The ratio of RS to RL is the release determining factor of the outer coating, and this ratio can be from 0:100 to 100:0. Optionally, plastisizers can be added to the polymer film to enhance its characteristics. Also, dissolution modifiers can be added to the outer coating to enhance the dissolution, which excipients can be e.g. polyethylene glycol, mono-, di-, or polysaccharides like e.g. hydroxypropylmethylcellulose, carboxy- methylcellulose, xanthan gum, lactose or sucrose.

Advantageously, a third coating can be applied to the coated tablet, a s.c. "sealcoat" which e.g. can be composed of a mixture of methylcellulose, propylene glycol and silicone liquid. The sole purpose of this sealcoat is to improve the shelf-life of the coated tablets of the invention.

If desired, a multiple unit dosage form can be prepared by filling two or more tablets according to the invention into a hard gelatine capsule.

Biologically active agents

The biologically active agents which can be incorporated into the release-controlled coated tablets are any substance which posses a therapeutic or any other beneficial action, e.g. steroids like hydrocortisone, budesonide, triamcinolone or prednisone; NSAIDS like e.g. diclofenac sodium, piroxicam, aspirin or ketoprofen; analgetic agents like e.g. codein, morphine, oxycodone or dihydromorhpone; antibiotics like e.g. amoxycillin, clavulanic acid or erythromycin, antimicrobic agents for the urogenital tract like e.g. nitrofurantoin, nalidixic acid or pipemidic acid, antihistamines and/or antiasthamatics like e.g. ephedrine, terfenadine, theophyllin or methylprednisolone; broncodilators like e.g. albuterol, salbutamol or terfenadine; antiemitics like e.g. metoclopramide; antiviral drugs like e.g. acyclovir, ribavirin or AZT; anti ulcer drugs like e.g. ranitidine or cimetidine; Anti-parkinson drugs like levodopa, carbidopa or benserazide; diuretics like e.g. furosemide or thiazides; calcium antagonists like e.g. diltiazem, nifedipine or verapamil; drugs for treatment of hypertension like eg. ace-inhibitores (ramipril, captopril) beta-blockers (pindolol, metoprolol, sotalol) or other drugs for treatment of cardiovascular diseases like organic nitrates, e.g. nitroglycerin, isosorbide mono- or dinitrate. The active agents can be in the form of salts or derivatives, and can be administrated as a single drug or combinations of two or more drugs.

In a preferred embodiment of the invention, the active substances are drugs for treatment of various diseases associated with pain, inflamma ti on, hypertension and/or heart conditions

In still another preferred embodiment the active substance is selected from ketoprofen, morphine, metoprolol and isosorbide-5-mononitrate.

Mode of action.

When a dual-coated tablet of the present invention is ingested by a patient, the tablet normally resides in the stomach for 1-2 hours. The outer coating posses the ability to swell and thereby becomes permeable for water and dissolved drugs. The permeability of the outer coating is determined by the thickness of the coating and, when the outer coating consists of a mixture of Eudragit®RS and Eudragit®RL, by the ratio of Eudragit®RS to Eudragit®RL . The outer coating begins to swell immediately after contact with liquid. When the swelling of the outer coating starts, in acidic medium, the enteric coating will prevent the core from disintegrating. After 1-6 hours, the inner coating is dissolved, and the biologically active agent will diffuse into the intestine. The prolonged release is dependent of the permeability and degradation of the coating material. The present invention further relates to a process for preparing a tablet as defined in claim 1 comprising the steps of 1) mixing and compressing ingredients a) to form a core, 2) applying a solution/dispersion of the enteric coating b) in a first solvent onto the core and drying the coated core to remove the first solvent and 3) applying a solution/dispersion of the outer coating c) in a second solvent onto the coated core and drying the double-coated core to remove the second solvent.

In a preferred embodiment of the process of the invention, the biologically active agent is isosorbide-5- mononitrate, the core materials are anhydrous calcium hydrogen phosphate , lactose, microcrystalline cellulose, polyvinylpyrrolidone, talc and magnesium stearate, the inner coating is Eudragit®L 30 D and the outer coating is Eudragit®RL or a mixture of Eudragit®RS and Eudragit®RL.

The invention also relates to a tablet as defined in claim 1 for use as a medicament.

Furthermore, the invention relates to the use of a tablet as defined in claim 1 in the manufacture of a medicament for the treatment of angina pectoris or other heart diseases .

Finally, the invention relates to a method of treating angina pectoris or other heart diseases, wherein a tablet as defined in claim 14 is administrated to a patient in need thereof. Preferably, the tablet is administrated to the patient at bedtime to prevent pre-wakening or early morning angina pectoris. Description of the drawings

Figures 1-5 each demonstrate the dissolution profiles of 6 tablets as a function of time. Each tablet has been measured individually. Figure 6 and 7 show the dissolution profiles of the coated tablet as a mean value of 6 tablets.

Figure 1 and Figure 3 show the dissolution of a coated tablet, in which part A of the core is absent.

Figure 2 shows the dissolution of a coated tablet, in which core a too large excess of part A has been used.

The results clearly demonstrate that the ratio between the excipients in the core of the coated tablet is a critical factor.

Figure 4 shows the dissolution of a first coated tablet according to the invention.

Figure 5 shows the dissolution of a second coated tablet according to the invention.

Figure 6 shows the dissolution of coated tablets according to the invention. Example 5 include 5-ISMN, Example 6 include metoprolol succinate and Example 7 include morphine hydrochloride . The results show that the diffusion rate of the drugs through the films depends on the physical and chemical properties of the drugs.

Figure 7 shows dissolution of coated tablets according to the invention. Example 8 include 5-ISMN, Example 9 include metoprolol succinate, Example 10 include morphine hydrochloride and Example 11 include ketoprofen. The following, non-limiting Examples illustrate the preparation of the controlled release tablet for oral administration.

EXAMPLE 1

The core

Materials Each tablet contains:

Isosorbide-5-mononitrate 60 mg

Lactose 189 mg

Microcrystalline Cellulose (Avicel pH 101) 30 mg

Carboxymethylcellulose sodium (Ac-Di-sol) 12 mg Polyvinylpyrrolidon (Kollidon 30) 3 mg

Magnesium Stearate 3 mg

Talc 3 mg

Methods

The cores are being produced by wet granulation in a blade mixer. The binder solution contains 8% Kollidon 30 in ethanol/ purified water 50:50. The tablets are pressed in any tablet compression machine. The average weight of the core is 300 mg.

The inner coating

Materials The spray suspension contains:

Methacrylic Acid copolymer (Eudragit L30D) 513.0 g

Triethylcitrate (Eudraflex) 15.4 g

Talc 93.6 g

Antifoam emulsion 2.0 g Purified water 500.0 g Methods

2200 g cores are being introduced into the fluidized-bed machine Glatt GPCG with the Wurster insert. The inlet-air is 34-37°C. The nozzle is placed as a bottom spray system and with a nozzle pressure of 2 atm. The product temperature is 34-35°C. The spraying rate is about 15 g/ml. The fluidized air velocity is 180-181 m3 /hour. The cores are sprayed for a period of about 60 minutes. The tablets are finally removed from the coating machine and spread out on trays and dried at 40°C for 4 hours.

The outer coating

Materials:

The spray suspension contains:

Ammoniomethacrylate copolymer (Eudragit RL30D) 167.0 g

Ammoniomethacrylate copolymer (Eudragit RS30D) 167.0 g

Triethylcitrate (Eudraflex) 20.0 g Talc 50.0 g

Antifoam emulsion 0.6 g

Purified water 366.0 g

Methods

The tablets are coated in the fluidized-bed machine Glatt GPCG with the Wurster insert. The inlet-air is 34-41°C. The nozzle is placed as a bottom spray system and with a nozzle pressure of 2 atm. The product temperature 33- 35°C. The spraying rate is about 15 g/ml. The fluidized air velocity is 180-181 m3/hour. The cores are sprayed for a period of about 60 minutes. The tablets are finally removed from the coating machine and spread out on trays and dried at 40°C for 10 hours. EXAMPLE 2.

The core

Materials

Each tablet contains:

Isosorbide-5-mononitrate 60 mg

Lactose 15 mg

Microcrystalline Cellulose (Avicel pH 101) 30 mg Dibasic calciumphosphate (Emcompresss) 186 mg

Polyvinylpyrrolidon (Kollidon 30) 3 mg

Magnesium stearate 3 mg

Talc 3 mg

The cores are compressed and coated analogous with Example 1.

EXAMPLE 3.

The core

Materials

Each tablet contains:

Isosorbide-5-mononitrate 60 mg Lactose 201 mg

Microcrystalline Cellulose (Avicel pH 101) 30 mg

Polyvinylpyrrolidon (Kollidon 30) 3 mg

Magnesium stearate 3 mg

Talc 3 mg

The cores are compressed and coated analogous with Example 1. EXAMPLE 4.

The core.

Materials

Each tablet contains:

Isosorbide-5-mononitrate 60 mg

Lactose 15 mg

Microcrystalline Cellulose (Avicel pH 101) 75 mg Polyethylene glycol 6000 6 mg

Caallcciiuumm hhyyddrrooggeenn pphhoosspphlxate dihydrate (Calstar) 135 mg Polyvinylpyrrolidon (Kollidon 30) 3 mg Magnesium stearate 3 mg Talc 3 mg

The cores are compressed and coated analogous with Example 1.

EXAMPLE 5

The core composition and the inner coating are analogous with Example 4.

The outer coating

Materials :

The spray suspension contains:

Ammoniomethacrylate copolymer (Eudragit RL30D) 251.00 g Ammoniomethacrylate copolymer (Eudragit RS30D) 84.00 g

Triethylcitrate (Eudraflex) 20.00 g

Talc 50.00 g

Antifoam emulsion 0.55 g

Purified water 403.00 g Methods

The tablets are coated in the fluidized-bed machine Glatt GPCG with the Wurster insert, analogous with the outer coating in Example 1.

EXAMPLE 6

The core composition is analogous with Example 4, but 5- ISMN is substituted with metoprolol succinate. The inner coating is analogous with Example 4, and the outer coating is analogous with Example 5.

EXAMPLE 7

The core composition is analogous with Example 4, but 5- ISMN is substituted with morphine hydrochloride. The inner coating is analogous with Example 4, and the outer coating is analogous with Example 5.

EXAMPLE 8

The core

Materials

Each tablet contains:

Isosorbide-5-mononitrate Ό U mg

Lactose 2 6 mg

Microcrystalline Cellulose (Avicel pH 101 75 mg Polyethylene glycol 6000 6 mg

Anhydrous calcium hydrogen phosphate (Emcompress, anhydrous) 124 mg

Polyvinylpyrrolidon (Kollidon 30) 3 mg The inner coating.

Materials

The spray suspension contains: Methacrylic Acid copolymer (Eudragit L30D) 333,00 g

Triethylcitrate (Eudraflex) 10,00 g

Talc 51,00 g

Antifoam emulsion 1,25 g

Purified water 294,00 g

The outer coating

Materials :

The spray suspension contains: Ammoniomethacrylate copolymer (Eudragit RL30D) 200,0 g

Triethylcitrate (Eudraflex) 12,0 g

Talc 30,0 g

Antifoam emulsion 0.3 g

Purified water 219,0 g

The cores are compressed and coated analogues with Example 1.

EXAMPLE 9

The core composition is analogous with Example 4, but 5- ISMN is substituted with metoprolol succinate. The two coatings are analogous with Example 8.

EXAMPLE 10

The core composition is analogous with Example 4, but 5- ISMN is substituted with morphine hydrochloride. The two coatings are analogous with Example 8. 22

EXAMPLE 11

The core composition is analogous with Example 4, but 5- ISMN is substituted with ketoprofen. The two coatings are analogous with Example 8.

Dissolution test

Dissolution of the 5-ISMN core, according to USP 23 p.1795-1796. Dissolution was performed by means of the basket method, the medium consisted of 0, 02M tribasic phosphate solution. The samples were analysed using Shimadzu UV-spectrophoto eter 220 nm.

Dissolution of 5-ISMN coated tablet according to USP 23 p.1795-1796. After 2 hours of operation in 0, IN hydrochloric acid, the pH was adjusted to 6,8 pH with 0,02M tribasic phosphate. The samples were analysed using Shimadzu UV-spectrophotometer 220nm, or HPLC; mobile phase methanol/ water 25:75, flow 0,8 ml/min, detection 230 nm by Shimadzu UV-spectrophotometer.

The samples from Examples 1 + 5 were analysed using HPLC and the samples from Examples 2+3+4 were analysed using UV at 220 nm. The coated tablets from Examples 7+10 were analysed using Shimadzu UV-spectrophotometer at 285 nm, the coated tablets from Examples 6+9 were analysed using Shimadzu UV-spectrophotometer at 274 nm, and the coated tablets from Example 11 were analysed using Shimadzu UV- spectrophotometer at 258nm. The values of the UV-analysis of Examples 6+7+9+10+11 were corrected for the absorbents of a placebo tablet.

Claims

CLAIMS :
1. A tablet suitable for oral administration being formed from the following ingredients:
a) an inner core containing a biologically active agent and conventional excipients (part B) and a pharmaceutically acceptable, water insoluble, non- swellable carrier (part A) , wherein part A constitutes from 20 % to 70 % by weight of the core,
b) an enteric coating, which prevents gastric fluid to enter into the core thereby preventing drug release in the stomach, but being soluble in the intestinale fluid (pH > 5) , and
c) an outer coating consisting of one or more polymer (s), the permeability of which is independent of pH.
2. A tablet according to claim 1, in which the water insoluble, non-swellable ingredient (s) of the core is/are selected from inorganic compounds.
3. A tablet according to claim 2, wherein the inorganic compound of the core is selected from alkaline-, alkaline earth- or aluminium salts, Ti02 or Si02.
4. A tablet according to claim 3, wherein the inorganic compound of the core is selected from calcium phosphate, calcium hydrogen phosphate, calcium sulphate, calcium carbonate, calcium silicate, calcium magnesium silicate, kaolin, magnesium oxide, magnesium carbonate or aluminium silicate or mixtures thereof.
5. A tablet according to claim 4, wherein the inorganic compound of the core is anhydrous calcium hydrogen phosphate .
6. A tablet according to any of the claims 1-5, in which the dissolution of the core, according to U.S. P. 23, p. 1795-96, releases no more than 60 % of the biologically active agent within the first 30 minutes and at least 90% after 3-9 hours.
7. A tablet according to any of claims 1-6, wherein the enteric . coating consists of a coating material selected from hydroxy propyl methyl cellulose phthalate, polyvinyl acetate phthalate, copolymers of acrylic- and/or methacrylic acid/esters or mixtures thereof.
8. A tablet according to claim 7 in which the enteric coating consists of copolymers of acrylic- and/or methacrylic acid/esters known as Eudragit® L30D .
9. A tablet according to any of the claims 1-8 wherein the outer coating is selected from one or more polymer (s) which can be ethylcellulose, polysiloxan, polyethylene or copolymers of acrylic- and/or methacrylic acids/esters.
10. A tablet according to claim 9 wherein the outer coating is selected from copolymers of acrylic- and/or methacrylic acids/esters known as Eudragit®RL, Eudragit ®RS or mixtures thereof.
11. A tablet according to any of the claims 1-10 wherein dissolution modifiers are present in the outer coating.
12. A tablet according to claim 11 wherein the dissolution modifiers are selected from polyethylen glycol, hydroxy methylpropylcellulose, carboxy- methylcellulose, xanthan gum, lactose or sucrose.
13. A tablet according to any of the claims 1-12 wherein the core consists of a biologically active agent, anhydrous calcium hydrogen phosphate, lactose, microcrystalline cellulose, polyvinylpyrrolidone, talc and magnesium stearate.
14. A tablet according to any of the preceding claims, wherein the biologically active agent is selected from morphine, ketoprofen, metoprolol and isosorbide-5- mononitrate .
15. A tablet according to any of the preceding claims, wherein the tablet has a lag time of 1-6 hours (release of biologically active agent < 10 %) , followed by release of biologically active agent for 3-12 hours (release > 80 o ; .
16. A process for the preparation of a tablet according to any of the claims 1-15 comprising the steps of 1) mixing and compressing ingredients a) to form a core, 2) applying a solution/dispersion of the enteric coating b) in a first solvent onto the core and drying the coated core to remove the first solvent and 3) applying a solution/dispersion of the outer coating c) in a second solvent onto the coated core and drying the double-coated core to remove the second solvent.
17. A process according to claim 16, in which the biologically active agent is morphine, ketoprofen, metoprolol or isosorbide-5-mononitrate, the core materials are anhydrous calcium hydrogen phosphate, lactose, microcrystalline cellulose, polyvinylpyrrolidone, polyethylene glycol, talc and magnesium stearate, the inner coating is Eudragit®L 30 D and the outer coating consists of Eudragit® RL.
18. A process according to claim 16, in which the biologically active agent is morphine, ketoprofen, metoprolol or isosorbide-5-mononitrate, the core materials are anhydrous calcium hydrogen phosphate, lactose, microcrystalline cellulose, polyvinyl- pyrrolidone, polyethylene glycol, talc and magnesium stearate, the inner coating is Eudragit®L 30 D and the outer coating is a mixture of Eudragit® RS and Eudragit® RL.
19. A tablet according to any of the claims 1-15 for use as a medicament.
20. Use of a tablet according to any of the claims 1-15 in the manufacture of a medicament for the treatment of pain, inflammation, hypertension, angina pectoris or other heart diseases.
21. A method of treatment of angina pectoris or other heart diseases wherein a tablet according to claim 14 is administrated to a patient in need thereof.
PCT/DK1997/000582 1996-12-20 1997-12-18 Release-controlled coated tablets WO1998027967A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK145696 1996-12-20
DK1456/96 1996-12-20

Publications (1)

Publication Number Publication Date
WO1998027967A1 true true WO1998027967A1 (en) 1998-07-02

Family

ID=8105028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1997/000582 WO1998027967A1 (en) 1996-12-20 1997-12-18 Release-controlled coated tablets

Country Status (1)

Country Link
WO (1) WO1998027967A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045356A1 (en) * 2000-11-20 2003-06-05 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings
US6893662B2 (en) 2000-11-20 2005-05-17 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
EP1545550A2 (en) * 2002-08-08 2005-06-29 Biovail Laboratories Inc. Isosorbide mononitrate compositions and methods of their use
US20090142378A1 (en) 2002-02-21 2009-06-04 Biovail Laboratories International S.R.L. Controlled release dosage forms
WO2010026993A1 (en) 2008-09-03 2010-03-11 武田薬品工業株式会社 Method for improving absorbability of preparation, and preparation having improved absorbability
US7780987B2 (en) 2002-02-21 2010-08-24 Biovail Laboratories International Srl Controlled release dosage forms
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US7906112B2 (en) 2003-12-19 2011-03-15 The Procter & Gamble Company Canine probiotic Lactobacilli
US7998473B2 (en) 2003-12-19 2011-08-16 The Procter & Gamble Company Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium
US8034601B2 (en) 2005-05-31 2011-10-11 The Procter & Gamble Company Feline probiotic bifidobacteria
WO2011136376A1 (en) 2010-04-30 2011-11-03 武田薬品工業株式会社 Enteric tablet
WO2011136373A1 (en) 2010-04-30 2011-11-03 武田薬品工業株式会社 Enteric tablet
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
JP2012107058A (en) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc Pharmaceutical dosage form with multiple coatings
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
JP2014513685A (en) * 2011-05-13 2014-06-05 エモーショナル ブレイン ビー.ブイ. Drug delivery system
US8809035B2 (en) 2003-12-19 2014-08-19 The Iams Company Canine probiotic Bifidobacterium
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US9192177B2 (en) 2005-05-31 2015-11-24 The Iams Company Feline probiotic Lactobacilli
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432966A (en) * 1979-12-10 1984-02-21 Roussel-Uclaf Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
EP0163000A2 (en) * 1984-02-01 1985-12-04 3 M Medica GmbH Pharmaceutical product in pellet form with a continuous sustained release
EP0277925A1 (en) * 1987-01-15 1988-08-10 Lejus Medical Aktiebolag Diuretic composition
WO1991016042A1 (en) * 1990-04-17 1991-10-31 Eurand International Spa Controlled release drug formulation
WO1994025010A1 (en) * 1993-04-27 1994-11-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Solid form of administration of isosorbide 5-mononitrate
WO1996026722A1 (en) * 1995-02-28 1996-09-06 Astra Aktiebolag Use of isosorbide-5-mononitrate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432966A (en) * 1979-12-10 1984-02-21 Roussel-Uclaf Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
EP0163000A2 (en) * 1984-02-01 1985-12-04 3 M Medica GmbH Pharmaceutical product in pellet form with a continuous sustained release
EP0277925A1 (en) * 1987-01-15 1988-08-10 Lejus Medical Aktiebolag Diuretic composition
WO1991016042A1 (en) * 1990-04-17 1991-10-31 Eurand International Spa Controlled release drug formulation
WO1994025010A1 (en) * 1993-04-27 1994-11-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Solid form of administration of isosorbide 5-mononitrate
WO1996026722A1 (en) * 1995-02-28 1996-09-06 Astra Aktiebolag Use of isosorbide-5-mononitrate

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6893662B2 (en) 2000-11-20 2005-05-17 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8580302B2 (en) * 2000-11-20 2013-11-12 Warner Chilcott Company, Llc Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2003045356A1 (en) * 2000-11-20 2003-06-05 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings
US7780987B2 (en) 2002-02-21 2010-08-24 Biovail Laboratories International Srl Controlled release dosage forms
US20090142378A1 (en) 2002-02-21 2009-06-04 Biovail Laboratories International S.R.L. Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
EP1545550A2 (en) * 2002-08-08 2005-06-29 Biovail Laboratories Inc. Isosorbide mononitrate compositions and methods of their use
EP1545550A4 (en) * 2002-08-08 2011-04-13 Circ Pharma Res And Dev Ltd Isosorbide mononitrate compositions and methods of their use
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US8840880B2 (en) 2003-12-19 2014-09-23 The Iams Company Canine probiotic bifidobacteria globosum
US8900569B2 (en) 2003-12-19 2014-12-02 The Iams Company Method of treating diarrhea in a canine
US8900568B2 (en) 2003-12-19 2014-12-02 The Iams Company Method of treating diarrhea in a canine
US9580680B2 (en) 2003-12-19 2017-02-28 Mars, Incorporated Canine probiotic bifidobacterium pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7998473B2 (en) 2003-12-19 2011-08-16 The Procter & Gamble Company Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium
US7906112B2 (en) 2003-12-19 2011-03-15 The Procter & Gamble Company Canine probiotic Lactobacilli
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8802158B2 (en) 2003-12-19 2014-08-12 The Iams Company Methods of use of probiotic Lactobacilli for companion animals
US8809035B2 (en) 2003-12-19 2014-08-19 The Iams Company Canine probiotic Bifidobacterium
US9821015B2 (en) 2003-12-19 2017-11-21 Mars, Incorporated Methods of use of probiotic bifidobacteria for companion animals
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal
US9427000B2 (en) 2005-05-31 2016-08-30 Mars, Incorporated Feline probiotic lactobacilli composition and methods
US8034601B2 (en) 2005-05-31 2011-10-11 The Procter & Gamble Company Feline probiotic bifidobacteria
US9192177B2 (en) 2005-05-31 2015-11-24 The Iams Company Feline probiotic Lactobacilli
US9404162B2 (en) 2005-05-31 2016-08-02 Mars, Incorporated Feline probiotic bifidobacteria and methods
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
WO2010026993A1 (en) 2008-09-03 2010-03-11 武田薬品工業株式会社 Method for improving absorbability of preparation, and preparation having improved absorbability
WO2011136376A1 (en) 2010-04-30 2011-11-03 武田薬品工業株式会社 Enteric tablet
WO2011136373A1 (en) 2010-04-30 2011-11-03 武田薬品工業株式会社 Enteric tablet
JP2014513685A (en) * 2011-05-13 2014-06-05 エモーショナル ブレイン ビー.ブイ. Drug delivery system
US9763884B2 (en) 2011-05-13 2017-09-19 Eb Ip Hybritabs B.V. Drug delivery system
JP2012107058A (en) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc Pharmaceutical dosage form with multiple coatings

Similar Documents

Publication Publication Date Title
US6027748A (en) Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption
US6372254B1 (en) Press coated, pulsatile drug delivery system suitable for oral administration
US4927640A (en) Controlled release beads having glass or silicon dioxide core
US5773031A (en) Acetaminophen sustained-release formulation
US6660382B2 (en) Process for manufacturing coated granules with masked taste and immediate release of the active principle
US6068859A (en) Controlled-release dosage forms of Azithromycin
US5472708A (en) Pulsatile particles drug delivery system
US6476006B2 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US5407686A (en) Sustained release composition for oral administration of active ingredient
US5871776A (en) Controlled-release nifedipine
US5529783A (en) Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
US6605300B1 (en) Oral pulsed dose drug delivery system
US5489436A (en) Taste mask coatings for preparation of chewable pharmaceutical tablets
US20070196491A1 (en) Drug delivery systems comprising weakly basic drugs and organic acids
US5316772A (en) Bilayered oral pharmaceutical composition with pH dependent release
US20050106247A1 (en) Modified release dosage forms of skeletal muscle relaxants
US6589553B2 (en) Controlled release oral dosage form
US5593694A (en) Sustained release tablet
US6905708B2 (en) Controlled release oral dosage form
US20020160046A1 (en) Delivery system for omeprazole and its salts
US20020031552A1 (en) Teste masked pharmaceutical particles
US20030072802A1 (en) Sustained release topiramate
US6156343A (en) Controlled release preparation
US5283065A (en) Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase